KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Operating Leases (2020 - 2025)

Historic Operating Leases for AbCellera Biologics (ABCL) over the last 6 years, with Q3 2025 value amounting to $137.1 million.

  • AbCellera Biologics' Operating Leases rose 10679.6% to $137.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $137.1 million, marking a year-over-year increase of 10679.6%. This contributed to the annual value of $60.7 million for FY2024, which is 2150.04% down from last year.
  • According to the latest figures from Q3 2025, AbCellera Biologics' Operating Leases is $137.1 million, which was up 10679.6% from $137.2 million recorded in Q2 2025.
  • In the past 5 years, AbCellera Biologics' Operating Leases registered a high of $137.2 million during Q2 2025, and its lowest value of $17.0 million during Q1 2021.
  • Moreover, its 5-year median value for Operating Leases was $66.5 million (2024), whereas its average is $65.3 million.
  • As far as peak fluctuations go, AbCellera Biologics' Operating Leases skyrocketed by 88016.15% in 2021, and later tumbled by 2150.04% in 2024.
  • Over the past 5 years, AbCellera Biologics' Operating Leases (Quarter) stood at $36.4 million in 2021, then skyrocketed by 125.9% to $82.3 million in 2022, then decreased by 5.93% to $77.4 million in 2023, then decreased by 21.5% to $60.7 million in 2024, then surged by 125.63% to $137.1 million in 2025.
  • Its Operating Leases stands at $137.1 million for Q3 2025, versus $137.2 million for Q2 2025 and $63.2 million for Q1 2025.